U.S., Aug. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07105228) titled 'Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept: A US Real-World Evidence Study' on July 08.
Brief Summary: This study will describe and estimate the incidence of Retinal Vasculitis (RV) events among patients and patient eyes receiving aflibercept intravitreal (IVT) (Eylea(R), aflibercept 2mg) therapy in US clinical practice.
The main objective is to describe demographic and clinical characteristics of patients receiving aflibercept 2mg injections, to estimate the incidence of RV and RV plus Intraocular Inflammation (IOI) following aflibercept 2mg injections and to describe characteristics of RV cases.
Study St...